ReviewPharmaceutics2019
Drug Combinations: Mathematical Modeling and Networking Methods.
Review in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 56 citations in OpenAlex.
- Vitamin A Modulates AHR Signaling and Restricts Zika Virus Replication in Human Retinal Pigment Epithelial Cells: Insights from Molecular Modeling and Antiviral Assays.Pathogens (Basel, Switzerland) · 2026Article
- Model-informed prediction of antiviral drug combination synergy from sparse data using complementary mechanistic and pharmacodynamic approaches.Frontiers in pharmacology · 2026Article
- Adjustment for day-to-day variability in the estimation of effective concentrations for the assessment of mixture toxicity.Archives of toxicology · 2025Article
- Cancer network pharmacology: multi-network regulatory mechanisms and future directions.Medical oncology (Northwood, London, England) · 2025Review
- Effects of Anti-Pseudomonal Agents, Individually and in Combination, With or Without Clarithromycin, on Growth and Biofilm Formation by Antibiotic-Susceptible and -Resistant Strains ofAntibiotics (Basel, Switzerland) · 2025Article
- Synergistic anticancer effect of CDRI-08 and abiraterone acetate against castration resistant prostate cancer targeting PI3K/Akt pathway.Iranian journal of basic medical sciences · 2025Article
- Bioinformatics Approaches in the Development of Antifungal Therapeutics and Vaccines.Current genomics · 2024Review
- Interactions of plumbagin with five common antibiotics against Staphylococcus aureus in vitro.PloS one · 2024Article
- Multifunctional nanoparticle-mediated combining therapy for human diseases.Signal transduction and targeted therapy · 2024Review
- Virtual drug screen reveals context-dependent inhibition of cardiomyocyte hypertrophy.British journal of pharmacology · 2023Article
- Review of Predicting Synergistic Drug Combinations.Life (Basel, Switzerland) · 2023Review
- Model-based prediction of progression-free survival for combination therapies in oncology.CPT: pharmacometrics & systems pharmacology · 2023Article
- Effect of storage age and containers on the physicochemical degradation of guggul oleo-resin.Scientific reports · 2023Article
- Model-based assessment of combination therapies - ranking of radiosensitizing agents in oncology.BMC cancer · 2023Article
- Complexation: An Interesting Pathway for Combining Two APIs at the Solid State.Pharmaceutics · 2022Article
- Optimized scaling of translational factors in oncology: from xenografts to RECIST.Cancer chemotherapy and pharmacology · 2022Article
- Editorial on the Special Issue: "Multidrug Combinations".Biomolecules · 2022Article
- Evaluation of synergism in drug combinations and reference models for future orientations in oncology.Current research in pharmacology and drug discovery · 2022Review
- Dosage strategies for delaying resistance emergence in heterogeneous tumors.FEBS open bio · 2021Article
- Drug-drug cocrystals: Opportunities and challenges.Asian journal of pharmaceutical sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatments consisting of mixtures of pharmacological agents have been shown to have superior effects to treatments involving single compounds. Given the vast amount of possible combinations involving multiple drugs and the restrictions in time and resources required to test all such combinations in vitro, mathematical methods are essential to model the interactive behavior of the drug mixture and the target, ultimately allowing one to better predict the outcome of the combination. In this review, we investigate various mathematical methods that model combination therapies. This survey includes the methods that focus on predicting the outcome of drug combinations with respect to synergism and antagonism, as well as the methods that explore the dynamics of combination therapy and its role in combating drug resistance. This comprehensive investigation of the mathematical methods includes models that employ pharmacodynamics equations, those that rely on signaling and how the underlying chemical networks are affected by the topological structure of the target proteins, and models that are based on stochastic models for evolutionary dynamics. Additionally, this article reviews computational methods including mathematical algorithms, machine learning, and search algorithms that can identify promising combinations of drug compounds. A description of existing data and software resources is provided that can support investigations in drug combination therapies. Finally, the article concludes with a summary of future directions for investigation by the research community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.